0B68 Waldman, Scott - Thomas Jefferson University - Thomas Jefferson University

Scott A.. Waldman, MD, PhD

Contact Dr. Waldman

132 South 10th Street
Suite 1170
Philadelphia, PA 19107

(215) 955-6086
(215) fax

Most Recent Peer-reviewed Publications

  1. Companion diagnostics at the intersection of personalized medicine and healthcare delivery
  2. A novel CDX2 isoform regulates alternative splicing
  3. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C
  4. Managing the innovation supply chain to maximize personalized medicine
  5. Antiobesity pharmacotherapy: New drugs and emerging targets
  6. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
  7. Policies to aid the adoption of personalized medicine
  8. Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy
  9. Molecular insights provide the critical path to disease mitigation
  10. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer
  11. Erratum: Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter randomized trial with lineage-specified biologics (Journal of the American College of Cardiology (2013) 61 (2329-2338))
  12. Genetics and genomics for the prevention and treatment of cardiovascular disease: Update a scientific statement from the american heart association
  13. Reply: The C-CURE randomized clinical trial (Cardiopoietic stem Cell therapy in heart failURE)
  14. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer
  15. Advances in cancer immunotherapy
  16. Colorectal cancer immunotherapy
  17. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis
  18. Evidence-based guidelines for precision risk stratification- based screening (PRSBS) for colorectal cancer: Lessons learned from the us armed forces: Consensus and future directions
  19. Molecular staging of node negative patients with colorectal cancer
  20. Systems approaches evolve clinical pharmacology